Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

• National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease.
• Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.
• Puppies treated with CPMA had a 93% survival rate and returned home an average of 1.87 days sooner.^1,2
• Elanco's ParvoTrack, the first-ever national online parvo tracking tool, allows pet owners and veterinarians to self-report outbreaks in real time, further highlighting the need for CPMA across the country and reinforcing Elanco's commitment to increasing the availability of CPMA.
• Texas, Arizona, Georgia, Florida, Illinois, Indiana and New York have some of the highest reported cases of canine parvovirus outbreaks according to ParvoTrack.

GREENFIELD, Ind., April 22, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today recognizes the second annual National Parvo Awareness Day, aimed at increasing awareness of canine parvovirus, a highly contagious and often-fatal puppy disease. Since receiving conditional approval from the USDA, Canine Parvovirus Monoclonal Antibody (CPMA) has helped save thousands of puppies.³ Although parvovirus can strike anytime, late spring and summer months are the most common for outbreaks nationwide.